Abstract 4989
Background
Gastric cancer (GC) is one of the most common lethal malignancies worldwide. Signet ring cell carcinoma (SRCC) is a poorly differentiated gastric cancer. The molecular characteristics and prognostic of SRCC are not well studied.
Methods
Formalin fixed paraffin embedded (FFPE) samples of 64 Chinese solid tumor patients were collected for next‐generation sequencing (NGS) based 450 genes panel assay. Genomic alterations including single base substitution, short and long insertions/deletions, copy number variations, gene fusions and rearrangement were assessed. Microsatellite stable (MSS) status and TMB (tumor mutational burden) were also acquired by an NGS algorithm.
Results
A total of 64 patients were identified as GC-SRCC through SRCC histology. The most frequently mutated genes were TP53(48%), CDH1(31%), ARID1A(14%), CDKN2A(9%), LRP1B(9%), KMT2D(6%), NF1(6%), ERBB2(9%) and GLI3(8%). Meanwhile, the copy numbers of FGFR2(14%), FGF3(8%), FGF19(8%), FGF4(8%), MYC(8%), CCND1(6%) and CDKN2A(9%) were frequently altered in SRCC.FGFR2 and 11q13 amplification is the first time reported in Chinese SRCC. Moreover, FGFR2 rearrangement (FGFR2/VTI1A and FGFR2/TACC2) was detected in 4% tumor samples. 34 cases had received chemotherapy, 4 cases had confirmed partial responses (PR); 14 cases had reached the stability of disease (SD). Noticeably, patients harboring gene rearrangement (N = 9) were observed a much shorter overall survival time (OS) in comparison with patients without any gene rearrangement (N = 14) (13.2 months vs 24.2 months, P < 0.05). Additionally, patients with CDH1 mutation (N = 9) showed a shorter OS than CDH1 wide type (N = 25) (14.2 months vs 25.3 months, P = 0.11), although the difference was not statistically significant.
Conclusions
Our observation reveals the molecular characteristics of SRCC. Gene rearrangements might associate to shorter OS. FGFR2 and 11q13 region amplification were newly observed in SRCC. It might provide new possibilities for the treatment of SRCC. Due to the limitations of the number of samples, the results may require further research and validation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract